You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies are working together to secure US Food and Drug Administration Emergency Use Authorization for the digital droplet PCR test.
The diagnostic firm has agreed with Streck to incorporate its blood collection tubes into sample collection protocols for its genomic lung cancer tests.
The firms will use Biodesix's biomarker discovery platform to analyze the proteome of pancreatic cancer patients treated with Immodulon's immunotherapy IMM-101.
Under the agreement, Biodesix will use the Thermo Fisher Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to generate data to apply for FDA premarket approval.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.